Cosmetic composition and method for retarding hair growth

Abstract

The present invention comprises cosmetic compositions and methods for retarding hair growth comprising a combination of an ornithine decarboxylase inhibitor, an anti-angiogenic active and an anti-inflammatory.

1 . A cosmetic composition comprising: 
 an ornithine decarboxylase inhibitor;    an anti-angiogenic active;    an anti-inflammatory; and    a cosmetically acceptable vehicle.    
     
     
         2 . The cosmetic composition of  claim 1  wherein the ornithine decarboxylace inhibitor is a pentacyclic triterpene selected from the group consisting of ursolic acid, betulin, betulinic acid, oleanolic acid, betulin mono and di-succinate or glutarate and polyethylene glycol and wherein the ornithine decarboxylace inhibitor is present in an amount from 0.1% to 50%.  
     
     
         3 . The cosmetic composition of  claim 1  wherein the anti-angiogenic active is a sphingo lipid selected from the group consisting of phytosphingosine, dihydrosphingosine, sphingosine and dehydrosphingosine and wherein the anti-angiogenic active is present in an amount of from 0.01% to 10%.  
     
     
         4 . The cosmetic composition of  claim 1  wherein the anti-angiogenic active is selected from the group consisting of magnolia extract, shark cartilage and tetrahydrocurcumin.  
     
     
         5 . The cosmetic composition of  claim 1  wherein the anti-inflammatory is selected from the group consisting of gorgonian extract, hoelen extract, ximenynic acid, hesperitin, tea polyphenols and licorice extract and wherein the anti-inflammatory is present in an amount from 0.0001% to 20%.  
     
     
         6 . The cosmetic composition of  claim 1  further comprising a whitening agent selected from the group consisting of yeast extract, ferulic acid, vitamin C derivatives, Na+ hinokitiol, licorice extract, extracts of mitracarpus scaber/bearberry, extracts of mulberry/scutellaria, arbutin, resveratrol and kojic acid.  
     
     
         7 . The cosmetic composition of  claim 1  further comprising a plant extract selected from the list consisting of soy extract, wild yarn and ginseng.  
     
     
         8 . The cosmetic composition of  claim 1  further comprising a 5 alpha reductase inhibitor selected from the group consisting of saw palmetto, woodworm (Artemisinin), liposome encapsulated azuleic acid (Azelosome), clove extract (Chouji Liquid), Zinc salt of L-Pyrrolidone Carboxylic Acid (Zincidoneg), mixture of water, hydrolyzed soy protein, 3-aminopropane, sulfonic acid and sodium chondroitin sulfate (Capigen), seaweed extract (Phlorogine), isolutrol, progesterone, (5,20-R)-4-diazo-21-hydroxy-20-methyl pregnan-3-one, (4R)-5-10-seco-19-Norpregna4,5-diene-3,10,20 trione, 4-androstene-3-one-17-carboxylic acid, and its methyl ester, 17-beta-N,N-diethylcarbamoyl-9-methyl-4-aza-5-alpha-androstane-3-one, 11-alpha-OH-progesterone, 17-alpha-OH-progesterone, and 20-alpha-OH-progesterone.  
     
     
         9 . A cosmetic composition comprising: 
 from 0.1 to 50% of a penticylic triterpene;    from 0.01 to 10% of a sphingo lipid;    from 0.0001 to 20% of gorgonian extract; and    a cosmetically acceptable vehicle.    
     
     
         10 . The cosmetic composition of  claim 9  wherein the pentacyclic triterpene is selected from the group consisting of ursolic acid, betulin, betulinic acid, oleanolic acid, betulin mono and di-succinate or glutarate and polyethylene glycol.  
     
     
         11 . The cosmetic composition of  claim 9  wherein the sphingo lipid is selected from the group consisting of phytosphingosine, dihydrosphingosine, sphingosine and dehydrosphingosine.  
     
     
         12 . The cosmetic composition of  claim 9  further comprising an anti-angiogenic active selected from the group consisting of magnolia extract, shark cartilage and tetrahydrocurcumin.  
     
     
         13 . The cosmetic composition of  claim 9  further comprising a whitening agent selected from the group consisting of yeast extract, ferulic acid, vitamin C derivatives, Na+ hinokitiol, licorice extract, extracts of mitracarpus scaber/bearberry, extracts of mulberry/scutellaria, arbutin, resveratrol and kojic acid.  
     
     
         14 . The cosmetic composition of  claim 9  further comprising a plant extract selected from the group consisting of soy extract, wild yarn, and ginseng.  
     
     
         15 . The cosmetic composition of  claim 9  further comprising a 5 alpha reductase inhibitor selected from the group consisting of saw palmetto, woodworm (Artemisinin), liposome encapsulated azuleic acid (Azelosome), clove extract (Chouji Liquid), Zinc salt of L-Pyrrolidone Carboxylic Acid (Zincidone®), mixture of water, hydrolyzed soy protein, 3-aminopropane, sulfonic acid and sodium chondroitin sulfate (Capigen), seaweed extract (Phlorogine), isolutrol, progesterone, (5,20-R)-4-diazo-21-hydroxy-20-methyl pregnan-3-one, (4R)-5-10-seco-19-Norpregna4,5-diene-3,10,20 trione, 4-androstene-3-one-17-carboxylic acid, and its methyl ester, 17-beta-N,N-diethylcarbamoyl-9-methyl-4-aza-5-alpha-androstane-3-one, 11-alpha-OH-progesterone, 17-alpha-OH-progesterone, and 20-alpha-OH-progesterone.  
     
     
         16 . A method for retarding the growth hair comprising applying a composition comprising 
 from 0.1 to 50% of an ornithine decarboxylase inhibitor;    from 0.01 to 10% of an anti-angiogenic active;    from 0.0001 to 20% of an anti-inflammatory; and    a cosmetically acceptable vehicle.    
     
     
         17 . The method of  claim 16  wherein the ornithine decarboylace inhibitor is a pentacyclic triterpene selected from the group consisting of ursolic acid, betulin, betulinic acid, oleanolic acid, betulin mono and di-succinate or glutarate and polyethylene glycol.  
     
     
         18 . The method of  claim 16  wherein the anti-angiogenic active is a sphingo lipid selected from the group consisting of phytosphingosine, dihydrosphingosine, sphingosine and dehydrosphingosine.  
     
     
         19 . The method of  claim 16  wherein the anti-angiogenic active is selected from the group consisting of magnolia extract, shark cartilage and tetrahydrocurcumin.  
     
     
         20 . The method of  claim 16  wherein the anti-inflammatory is selected from the group consisting of gorgonian extract, hoelen extract, ximenynic acid, hesperitin, tea polyphenols and licorice extract.  
     
     
         21 . The method of  claim 16  wherein the composition further comprises a whitening agent selected from the group consisting of yeast extract, ferulic acid, vitamin C derivatives, Na+ hinokitol, licorice extract, extracts of mitracarpus scaber/bearberry, extract of mulberry/scutellaria, arbutin, resveratrol and kojic acid.  
     
     
         22 . The method of  claim 16  wherein the composition further comprises a plant extract selected from the group consisting of soy extract, wild yarn and ginseng.  
     
     
         23 . The method of  claim 16  wherein the composition further comprises a 5 alpha reductase inhibitor selected from the group consisting of saw palmetto, woodworm (Artemisinin), liposome encapsulated azuleic acid (Azelosome), clove extract (Chouji Liquid), Zinc salt of L-Pyrrolidone Carboxylic Acid (Zincidone®), mixture of water, hydrolyzed soy protein, 3-aminopropane, sulfonic acid and sodium chondroitin sulfate (Capigen), seaweed extract (Phlorogine), isolutrol, progesterone, (5,20-R)-4-diazo-21-hydroxy-20-methyl pregnan-3-one, (4R)-5-10-seco-19-Norpregna4,5-diene-3,10,20 trione, 4-androstene-3-one-17-carboxylic acid, and its methyl ester, 17-beta-N,N-diethylcarbamoyl-9-methyl-4-aza-5-alpha-androstane-3-one, 11-alpha-OH-progesterone, 17-alpha-OH-progesterone, and 20-alpha-OH-progesterone.  
     
     
         24 . A method of retarding hair growth comprising applying a cosmetic composition comprising: 
 from 0.1 to 50% of a penticylic triterpene;    from 0.01 to 10% of a sphingo lipid;    from 0.0001 to 20% of gorgonian extract; and    a cosmetically acceptable vehicle.    
     
     
         25 . The method of  claim 24  wherein the pentacyclic triterpene is selected from the group consisting of ursolic acid, betulin, betulinic acid, oleanolic acid, betulin mono and di-succinate or glutarate and polyethylene glycol.  
     
     
         26 . The method of  claim 24  wherein the sphingo lipid is selected from the group consisting of phytosphingosine, dihydrosphingosine, sphingosine and dehydrosphingosine.  
     
     
         27 . The method of  claim 24  wherein the composition further comprises an anti-angiogenic active selected from the group consisting of magnolia extract, shark cartilage and tetrahydrocurcumin.  
     
     
         28 . The method of  claim 24  wherein the composition further comprises a whitening agent selected from the group consisting of yeast extract, ferulic acid, vitamin C derivatives, Na+ hinokitol, licorice extract, extracts of mitracarpus scaber/bearberry, extract of mulberry/scutellaria, arbutin, resveratrol and kojic acid.  
     
     
         29 . The method of  claim 24  wherein the composition further comprises a plant extract selected from the group consisting of soy extract, wild yarn, and ginseng.  
     
     
         30 . The method of  claim 24  wherein the composition further comprises a 5 alpha reductase inhibitor selected from the group consisting of saw palmetto, woodworm (Artemisinin), liposome encapsulated azuleic acid (Azelosome), clove extract (Chouji Liquid), Zinc salt of L-Pyrrolidone Carboxylic Acid (Zincidone®), mixture of water, hydrolyzed soy protein, 3-aminopropane, sulfonic acid and sodium chondroitin sulfate (Capigen), seaweed extract (Phlorogine), isolutrol, progesterone, (5,20-R)-4-diazo-21-hydroxy-20-methyl pregnan-3-one, (4R)-5-10-seco-19-Norpregna4,5-diene-3,10,20 trione, 4-androstene-3-one-17-carboxylic acid, and its methyl ester, 17-beta-N,N-diethylcarbamoyl-9-methyl-4-aza-5-alpha-androstane-3-one, 11-alpha-OH-progesterone, 17-alpha-OH-progesterone, and 20-alpha-OH-progesterone.